Vogt-Koyanagi-Harada disease
- PMID: 34545845
- DOI: 10.1097/ICU.0000000000000809
Vogt-Koyanagi-Harada disease
Abstract
Purpose of review: Here, we provide an overview of Vogt-Koyanagi-Harada disease (VKH), including recent updates in our understanding of disease pathophysiology, classification and therapeutics.
Recent findings: Advancements in bioinformatics, metabolomics and genomics investigations continue to illuminate VKH pathogenesis, and may provide insight into future therapeutic options. Multimodal imaging is indispensable in the initial evaluation of VKH, and is becoming increasingly important in understanding disease pathogenesis, as well as monitoring therapeutic response. Enhanced VKH classification criteria, released in 2021, provide standardized guidelines and terminology for clinical and research purposes.
Summary: Modern research and imaging techniques continue to improve our understanding of VKH; more work is needed to further elucidate pathogenic mechanisms and establish optimal therapeutic recommendations.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Vogt A. Frühzeitiges Ergrauen der Zilien und Bemerkungen über den sogenannten plötzlichen Eintritt dieser Veränderung. Klin Monatsbl Augenheilkd 1906; 44:228.
-
- Harada E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn 1926; 30:356–378.
-
- Koyanagi Y. Dysacousia, Alopecia und Poliosis bei schwere Uveitis nicht traumatischen Ursprungs. Klin Mblf Augenh 1929; 82:194–211.
-
- Herbort CP, Mochizuki M. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol 2007; 27:67–79.
-
- O’Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol 2017; 62:1–25.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials